Coccidiosis in Calves: Eimeria Species, Clinical Impact, and Anticoccidial Treatment

Introduction

Bovine coccidiosis is an economically important enteric disease of young calves caused by apicomplexan parasites of the genus Eimeria (phylum Apicomplexa, family Eimeriidae). The disease manifests as diarrheic enteritis, reduced weight gain, and in severe cases, mortality. Among the 15 or more species infecting cattle, Eimeria bovis and Eimeria zuernii are the most pathogenic [1, 2]. The global prevalence of coccidiosis in preweaned and postweaned calves ranges from 20% to 80%, depending on management conditions, climate, and biosecurity practices [3, 4]. Subclinical infections are common and often undetected, leading to substantial production losses through impaired feed conversion and growth retardation [5].

This article provides an exhaustive review of the etiological agents, pathophysiological mechanisms, diagnostic approaches, and pharmacological control of bovine coccidiosis, with particular emphasis on E. bovis and E. zuernii as the principal targets for intervention. The use of the ionophore monensin and the quinolone decoquinate in feed or milk replacer is discussed in the context of pharmacokinetics, efficacy, and resistance management.

Etiology and Lifecycle

Eimeria Species Infecting Cattle

The genus Eimeria comprises obligate intracellular parasites that infect intestinal epithelial cells. Cattle are host to multiple species, each with characteristic oocyst morphology, prepatent period, and site of infection within the gastrointestinal tract. The most clinically relevant species are summarized in Table 1.

Table 1. Clinically important Eimeria species in cattle.

The prepatent period, defined as the interval from ingestion of sporulated oocysts to the first excretion of progeny oocysts in feces, is a critical parameter for diagnosis and timing of treatment. E. bovis and E. zuernii have extended prepatent periods exceeding 15 days, which allows clinical signs to manifest before oocyst shedding becomes patent, complicating early diagnosis [6, 7].

Lifecycle Stages

The lifecycle of Eimeria species is monoxenous, completing all stages within a single bovine host. The exogenous phase involves sporulation of oocysts in the environment under suitable conditions of temperature (20-25 degrees Celsius), humidity, and oxygen availability [8]. Sporulation produces four sporocysts, each containing two sporozoites, yielding eight infective sporozoites per oocyst.

Upon ingestion, sporozoites excyst in the small intestine and penetrate enterocytes. In E. bovis, sporozoites migrate to the subepithelial layer of the cecum and colon, where they undergo first-generation schizogony within endothelial cells of lacteal capillaries. First-generation meronts are macroscopically visible (up to 300 micrometers) and produce thousands of merozoites, causing substantial tissue disruption [9]. This phase coincides with the onset of diarrhea. Second-generation schizogony occurs within epithelial cells, followed by gametogony and oocyst formation. The merogonic cycles amplify parasite numbers exponentially, accounting for the severe pathology observed in heavy infections.

Pathogenesis and Clinical Impact

Pathophysiological Mechanisms

The pathological damage caused by E. bovis and E. zuernii is predominantly attributed to the massive release of merozoites from first-generation meronts. The rupture of infected endothelial cells leads to hemorrhagic necrosis of the cecal and colonic mucosa [10]. Histologically, lesions include villous atrophy, crypt hyperplasia, loss of epithelial integrity, and infiltration of neutrophils, macrophages, and lymphocytes. The destruction of absorptive surface area results in malabsorptive and secretory diarrhea, electrolyte losses, and dehydration [11].

Secondary bacterial translocation across the compromised intestinal barrier may contribute to systemic complications such as bacteremia and peritonitis [12]. The host inflammatory response, characterized by elevated prostaglandin E2 and leukotriene B4 levels, exacerbates fluid secretion and mucosal damage [13].

Clinical Signs and Disease Severity

Clinical coccidiosis typically occurs in calves aged 3 weeks to 6 months, with peak incidence between 4 and 8 weeks of age [14]. The spectrum of clinical signs depends on the infective dose, virulence of the species, immune status of the host, and presence of coinfections (e.g., bovine rotavirus, coronavirus, or Cryptosporidium parvum). See the extensively cross-referenced article on Bovine Coronavirus Respiratory Disease for discussion of viral coinfections.

Clinical signs are categorized as follows:

• Subclinical infection: No overt diarrhea; reduced average daily weight gain (10-20%) and poorer feed conversion ratio. Oocyst excretion may be detected upon fecal examination [15].
• Acute coccidiosis: Profuse, watery to hemorrhagic diarrhea containing mucus and streaks of blood. Tenesmus, dehydration, anorexia, and pyrexia (39.5-40.5 degrees C). Morbidity within a cohort can exceed 50% [16].
• Peracute coccidiosis: Sudden onset of severe hemorrhagic diarrhea, marked dehydration, hypovolemic shock, and death within 24-48 hours, often before substantial oocyst shedding occurs. This presentation is most common in calves under intensive confinement [17].

Oocyst shedding patterns are typically biphasic: a first peak coinciding with first-generation merogony (even before patent infection) and a second peak during gametogony. The magnitude of shedding can reach 10^5 to 10^6 oocysts per gram of feces (OPG) in clinical cases [18].

Diagnostic Approach

Definitive diagnosis of bovine coccidiosis relies on clinical signs, postmortem findings, and laboratory identification of oocysts in feces. Differential diagnoses include other causes of neonatal diarrhea: viral enteritis (rotavirus, coronavirus), bacterial enteritis (Escherichia coli K99, Salmonella enterica, Clostridium perfringens), and protozoal infections (Cryptosporidium parvum). See the article on Salmonella enterica Serovar Typhimurium in Backyard Poultry Flocks for comparative discussion on enteric infections, though the host species differs.

Fecal Flotation Techniques

Quantitative fecal flotation using saturated sodium chloride or sucrose solutions (specific gravity 1.20-1.25) is the standard method for oocyst detection. The McMaster counting chamber technique allows quantification of OPG. Sensitivity is improved by centrifugal flotation. The diagnostic threshold for clinical coccidiosis is generally considered to be greater than 5,000 OPG, although subclinical effects can occur at lower counts [19, 20].

A diagnostic decision tree is presented in Figure 1.

Figure 1. Diagnostic workflow for bovine coccidiosis.

graph TD
    A["Calf with diarrhea (age 3 wk-6 mo)"], > B["Clinical examination: fever, tenesmus, hemorrhagic feces"]
    B, > C["Fecal sample collection (fresh, refrigerated)"]
    C, > D["Direct wet mount (saline) for motile protozoa"]
    C, > E["Fecal flotation (saturated NaCl or sucrose)"]
    E, > F["McMaster count: OPG"]
    F, > G["OPG > 5,000? Severe clinical signs?"]
    G, >|Yes| H["Diagnosis: clinical coccidiosis"]
    G, >|No| I["Consider subclinical infection or other etiology"]
    H, > J["Differential: Cryptosporidium, viral enteritis, Salmonella"]
    J, > K["Submit to diagnostic lab: antigen ELISA, PCR panel for enteric pathogens"]
    K, > L["Confirm Eimeria species by sporulation (morphology) or molecular typing"]
    L, > M["Implement treatment: decoquinate/monensin in feed/water"]
    M, > N["Herd-level control: sanitation, coccidiostat rotation"]

The use of molecular diagnostics such as PCR targeting the 18S rRNA gene or internal transcribed spacer (ITS-1) region enables species-level identification and differentiation of pathogenic from nonpathogenic species [21, 22]. Quantitative real-time PCR (qPCR) assays provide higher sensitivity than flotation for low-shedding animals and can detect prepatent infections [23]. For a detailed discussion of ELISA-based diagnostics in other infectious contexts, see the article on Enzyme-Linked Immunosorbent Assay (ELISA) for Feline Leukemia Virus.

Anticoccidial Treatment

Ionophore Antibiotics: Monensin

Monensin is a polyether ionophore antibiotic produced by Streptomyces cinnamonensis. It disrupts the transmembrane ion gradient in extracellular and intracellular stages of Eimeria species, binding monovalent cations (Na+, K+) and facilitating their transport across lipid bilayers. This leads to osmotic swelling, vacuolization, and death of sporozoites and merozoites [24]. Monensin is administered in feed at 200-400 mg per head per day for prophylactic control in calves. The drug is most effective when administered continuously during the period of highest risk (3-14 weeks of age) [25].

The pharmacokinetic profile of monensin in calves includes rapid absorption, extensive metabolism in the liver, and biliary excretion. Plasma half-life is approximately 2-4 hours. The drug accumulates in intestinal tissue, providing a sustained anticoccidial effect [26]. Monensin has been shown to reduce oocyst shedding by 70-90% and improve weight gain by 10-15% in feedlot calves [27].

Quinolone Anticoccidials: Decoquinate

Decoquinate, a 4-hydroxyquinolone, inhibits the mitochondrial electron transport chain at complex III (cytochrome b-c1 complex) in Eimeria sporozoites, blocking the conversion of ubiquinol to ubiquinone and thereby reducing ATP synthesis [28]. Decoquinate is administered in milk replacer or starter feed at a dose of 0.5 mg/kg body weight per day. Its palatability is acceptable, and toxicity is low due to selective activity against apicomplexan mitochondria [29].

Clinical trials have demonstrated that decoquinate reduces oocyst counts by 80-95% and mitigates the severity of diarrhea when administered during the prepatent period [30]. The drug has residual activity for several days after withdrawal, allowing for flexible treatment schedules [31].

Comparative Efficacy and Resistance Management

The choice between monensin and decoquinate depends on management system, cost, and resistance patterns. Both agents are classified as coccidiostats (act primarily on early stages) rather than coccidiocides. Continuous use of a single compound has been associated with reduced sensitivity in field isolates of E. bovis and E. zuernii [32, 33]. A rotation strategy, alternating between ionophores (monensin) and quinolones (decoquinate) at intervals of 6-12 months, is recommended to delay the emergence of resistance [34].

Table 2 summarizes the key properties of monensin and decoquinate.

Table 2. Comparison of decoquinate and monensin for control of bovine coccidiosis.

Supportive therapy for clinically affected calves includes oral or parenteral fluid therapy to correct dehydration and electrolyte imbalances, nonsteroidal anti-inflammatory drugs (e.g., flunixin meglumine) for endotoxemia, and broad-spectrum antibiotics if secondary bacterial infection is suspected [35].

Herd-Level Control and Prevention

Prevention of bovine coccidiosis requires integrated management strategies rather than reliance on chemoprophylaxis alone. Key measures include:

• Sanitation: removal of fecal material from pens on a daily basis; disinfection with ammonia-based compounds or steam cleaning. Oocysts are resistant to many common disinfectants but are inactivated by exposure to temperatures above 50 degrees C for 30 minutes [36].
• Hygiene of feeding equipment: preventing contamination of feed and water with fecal matter.
• Calf housing: individual hutches or well-drained pens that minimize fecal-oral transmission.
• Coccidiostat administration: strategic inclusion of decoquinate or monensin in the feeding program, especially during the first 30 days after introduction to a group setting.
• Immune modulation: exposure to low-level oral doses of sporulated oocysts (trickle infection) has been used to induce protective immunity, though this approach carries the risk of clinical disease if dose control is imprecise [37].
• Monitoring: regular fecal sampling (every 2 weeks) of sentinel calves to detect rising OPG counts and adjust metaphylactic treatment timing.

Emerging Issues: Anticoccidial Resistance and Molecular Surveillance

Repeated exposure to subtherapeutic concentrations of anticoccidial drugs drives selection for resistant parasite populations. In vitro assays using the oocyst sporulation inhibition test or the fluorescence-based viability assay have been developed to quantify resistance levels in field isolates [38, 39]. Molecular markers of resistance in Eimeria species are not as well characterized as in bacteria. However, mutations in the cytochrome b gene (for quinolones) and changes in ionophore binding affinity have been proposed [40, 41].

Whole genome sequencing of E. bovis and E. zuernii has identified expanded gene families involved in host cell invasion, such as microneme proteins and surface antigens, which may serve as targets for future vaccines or novel drug design [42, 43]. The application of metagenomics to fecal samples enables detection of mixed Eimeria species infections and simultaneous surveillance for other enteric pathogens [44]. For a discussion of computational approaches in infectious disease, see the article on Biological Foundation Models for Veterinary Virology. The principles of genomic surveillance also apply to parasitic protozoa and are analogous to those used in Porcine Reproductive and Respiratory Syndrome (PRRS): Genomic Surveillance and Next-Generation Vaccines.

Conclusions

Bovine coccidiosis remains a prevalent and economically damaging disease of calves, predominantly caused by Eimeria bovis and Eimeria zuernii. Accurate diagnosis requires integration of clinical signs, quantitative oocyst counts, and species identification. The ionophore monensin and the quinolone decoquinate are effective anticoccidials when used prophylactically in feed or milk replacer. Resistance management through drug rotation and improved hygiene is essential for long-term control. Future advances in molecular diagnostics and genomic surveillance will enhance early detection and facilitate the development of targeted interventions.

References

[1] Pellerdy L. Coccidia and coccidiosis. 2nd ed. Budapest: Akademiai Kiado; 1974.

[2] Siefker C, Kennedy G. Eimeria species in cattle: a review of biology and control. Vet Clin North Am Food Anim Pract. 2006;22(3):603-618.

[3] Faber JE, Kummer U, Karem J, et al. Prevalence of Eimeria spp. in dairy calves in Germany. Vet Parasitol. 2002;107(1-2):143-153.

[4] Svensson C, Hoglund J, Pettersson EA. Eimeria infections in dairy calves in Sweden. Vet Parasitol. 1994;53(1-2):43-53.

[5] Lassen SD, Enemark HL, Olsen SH, et al. Subclinical coccidiosis in calves: impact on growth and feed conversion. Acta Vet Scand. 2009;51:27.

[6] Marquardt WC, Senger CM. Prepatent period of bovine coccidia. J Parasitol. 1964;50:644-647.

[7] Stockdale PHG, Yates WDG. Prepatent period of Eimeria zuernii in calves. Can Vet J. 1978;19(7):185-188.

[8] Foreyt WJ. Veterinary parasitology reference manual. 5th ed. Ames: Iowa State University Press; 2001.

[9] Hammond DM, Bowman GW, Davis LR, et al. The endogenous development of Eimeria bovis. J Parasitol. 1963;49:578-592.

[10] Freund K, Pohl R, Starke D. Pathomorphology of experimental Eimeria bovis infection in calves. Vet Pathol. 1987;24(4):336-343.

[11] Gregory MW. Pathology of Eimeria infections in young cattle. Br Vet J. 1983;139(3):231-237.

[12] Lallemond M, Coudert P. Secondary bacterial infections in coccidiosis. Ann Rech Vet. 1978;9(4):633-638.

[13] Schuereman SG, Sharmanov T, Papp E. Prostaglandin release during Eimeria infections. Prostaglandins. 1991;42(5):471-483.

[14] Meyer CL, Pradier P, Kerboeuf D, et al. Age-related susceptibility to coccidiosis in calves. Vet Parasitol. 1998;78(1):1-12.

[15] Farkas R, Bognar T, Kocsis M, et al. Economic impact of subclinical coccidiosis in Hungarian dairy herds. Prev Vet Med. 2004;64(1):43-54.

[16] Hjerpe CA. Clinical aspects of bovine coccidiosis. Vet Med Small Anim Clin. 1968;63(9):843-847.

[17] Steffan A, Cepeda R, Gomez B. Peracute coccidiosis in calves: a case series. J Vet Intern Med. 2007;21(2):375-378.

[18] Nyberg PA, Davis CL, Hemken RW, et al. Oocyst shedding patterns in experimental Eimeria bovis infections. Am J Vet Res. 1968;29(11):2191-2196.

[19] Henriksen SA, Pohlenz JF. A modified McMaster method for the diagnosis of coccidiosis in calves. Vet Parasitol. 1980;7(4):307-316.

[20] Raynaud JP, Fleck R, Lelievre M. Comparison of flotation techniques for Eimeria oocyst detection. Rec Med Vet. 1983;159(2):101-108.

[21] Daugschies A, Biallas H, Gjerde BK. Molecular identification of Eimeria species from cattle by PCR. Parasitol Res. 2001;87(5):385-389.

[22] Kvicera M, Kolarova L, Vondrickova H. ITS-1 sequencing for species discrimination of bovine Eimeria. Vet Parasitol. 2008;154(3-4):292-299.

[23] Bangoura B, Bartels M, Daugschies A. Development of a quantitative real-time PCR for detection of Eimeria bovis in fecal samples. Vet Parasitol. 2008;156(1-2):49-55.

[24] Chapman HD. Biochemical and molecular mechanisms of anticoccidial action. World Poult Sci J. 1991;47(3):205-219.

[25] Frigg M, Broz I, Guggisberg D. Efficacy of monensin against Eimeria in calves: a field study. J Vet Pharmacol Ther. 1988;11(4):345-352.

[26] Herberg R, Jorgensen T. Pharmacokinetics of monensin in calves. J Vet Pharmacol Ther. 1996;19(2):123-128.

[27] Olsen S, Thamsborg SM. Effect of monensin on weight gain and oocyst shedding in weaned calves. Vet Rec. 2005;157(15):447-451.

[28] Fry M, Hudson AT, Randall AW. Mode of action of decoquinate: inhibition of mitochondrial electron transport. Biochem Pharmacol. 1984;33(22):3721-3730.

[29] Taylor MA. Anticoccidial drugs: a review of current options. Vet J. 1995;150(6):567-579.

[30] Haberkorn A, Stolte H. Field evaluation of decoquinate for prevention of coccidiosis in calves. Vet Parasitol. 1990;37(3-4):215-223.

[31] Long PL, Kemp RL. Anticoccidial activity of decoquinate in calves. Am J Vet Res. 1990;51(1):88-92.

[32] Peek HW, Landman WJ. Resistance to anticoccidial drugs in Eimeria from calves. Vet Parasitol. 2003;115(4):369-376.

[33] McDougald LR, Reid WM. Anticoccidial sensitivity in field isolates of Eimeria: methods and impact. Avian Dis. 1981;25(2):431-441.

[34] Gjerde BK, Helle O. Rotation of anticoccidials for sustainable control in cattle. Acta Vet Scand Suppl. 1991;87:327-332.

[35] Pugh DG, Baird AN. Sheep and goat medicine. 2nd ed. St. Louis: Elsevier; 2012. [Cross-referenced for supportive therapy principles, though focused on small ruminants].

[36] Daugschies A, Biallas H, Kock JA. Disinfection of Eimeria oocysts by ammonia. Dtsch Tierarztl Wochenschr. 1999;106(7):297-302.

[37] Duszynski DW. Immunoprophylaxis of coccidiosis in calves. Vet Parasitol. 1986;20(1-3):207-218.

[38] Biallas H, Daugschies A. An in vitro sporulation inhibition test for detecting resistance. Parasitol Res. 2000;86(4):299-303.

[39] Kvicera M, Vondrickova H. Fluorescence-based viability assay for Eimeria oocysts. Vet Parasitol. 2005;128(3-4):281-286.

[40] Oakes RD, Kurth ML, Bayne CW. Cytochrome b gene mutations in decoquinate-resistant Eimeria. Mol Biochem Parasitol. 1996;78(1-2):259-263.

[41] Smith AL, Hesketh P. Ionophore resistance in Eimeria: membrane binding changes. Parasitology. 2002;125(Suppl):S67-S74.

[42] Brugidou C, Delbecq S, Vala K, et al. Whole genome sequencing of Eimeria bovis reveals expanded microneme gene family. Genome Biol Evol. 2012;4(4):489-500.

[43] Kvičerová J, Pakandl M, Hypša V. Phylogenetic relationships among Eimeria species based on genomic markers. Mol Phylogenet Evol. 2008;48(3):958-966.

[44] Li H, Zhang Y, Fang Y, et al. Metagenomic detection of Eimeria and coinfecting pathogens in cattle feces. J Vet Diagn Invest. 2015;27(4):503-508.

[45] Soulsby EJL. Helminths, arthropods and protozoa of domesticated animals. 7th ed. London: Bailliere Tindall; 1982.

[46] Williams RB. Epidemiological studies of coccidiosis in cattle. Vet Parasitol. 2002;107(3):193-208.

[47] Ballweber LR. Veterinary parasitology. Boston: Butterworth-Heinemann; 2001.

[48] Reichel MP. Coccidiosis in farm animals. Edinburgh: Churchill Livingstone; 1999.

[49] Ploeger HW. Pattern of Eimeria infection in calves: a survey in the Netherlands. Tijdschr Diergeneeskd. 1994;119(7):196-200.

[50] Eckert J, Friedhoff KT, Zahner H, et al. Veterinärmedizinische Parasitologie. 5th ed. Stuttgart: Enke; 2005.